Key statistics
On Tuesday, Lyell Immunopharma Inc (LYEL:NSQ) closed at 9.05, 18.30% above the 52 week low of 7.65 set on Jun 02, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.66 |
---|---|
High | 9.83 |
Low | 9.03 |
Bid | 9.10 |
Offer | 9.18 |
Previous close | 9.67 |
Average volume | 48.45k |
---|---|
Shares outstanding | 15.43m |
Free float | 11.31m |
P/E (TTM) | -- |
Market cap | 149.24m USD |
EPS (TTM) | -24.32 USD |
Data delayed at least 15 minutes, as of Jul 15 2025 20:40 BST.
More ▼
- Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series
- Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma
- Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments
- Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
- Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025
- Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025
- Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma
- Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024
- Lyell Immunopharma Announces Participation in Upcoming Investor Conferences
- Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference
More ▼